Want to see JSPR full AI Analyst Report?
Top Page
Jasper Therapeutics
(NASDAQ:JSPR)
Select Model
Select Model
Rating:40Underperform
Price Target:
$0.43
▼(-57.75% Downside)
Action:Reiterated
Date:07/02/26
The score is driven primarily by weak financial performance (pre-revenue, sizable losses, and heavy cash burn with a diminished equity cushion). Technicals also remain bearish with the stock below all key moving averages and negative MACD. Corporate events add further downside uncertainty due to Nasdaq bid-price non-compliance and a strategic alternatives review that includes high-risk outcomes.
Positive Factors
Low leverage
Absolute debt is very low relative to operating needs, which reduces near-term interest burden and financial distress risk. Over a multi-month horizon this preserves strategic optionality to prioritize R&D or seek partnerships without immediate lender pressure, a durable balance-sheet advantage.
Negative Factors
High cash burn / pre-revenue
Sustained negative operating and free cash flow without revenue erodes runway and forces reliance on external financing, which raises dilution risk and constrains strategic choices. Over the next 2-6 months this structural cash deficit materially increases the probability of asset sales, partnerships, or funding actions.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Absolute debt is very low relative to operating needs, which reduces near-term interest burden and financial distress risk. Over a multi-month horizon this preserves strategic optionality to prioritize R&D or seek partnerships without immediate lender pressure, a durable balance-sheet advantage.
Read all positive factors
Jasper Therapeutics (JSPR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$12.00M
Dividend YieldN/A
Average Volume (3M)399.98K
Price to Earnings (P/E)―
Beta (1Y)2.83
Revenue GrowthN/A
EPS Growth38.53%
CountryUS
Employees22
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.40
Shares Outstanding28,009,802
10 Day Avg. Volume455,991
30 Day Avg. Volume399,984
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)8.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.45
Enterprise Value/Market Cap-0.48
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit272.64
Enterprise Value/Ebitda0.10
Forecast
1Y Price Target
$3.00Price Target Upside194.12% Upside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)-1.11
Revenue Forecast (FY)N/A
Jasper Therapeutics Business Overview & Revenue Model
Company Description
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed t...
How the Company Makes Money
null...
Jasper Therapeutics Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
28
Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -21.00K | -1.06M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -54.94M | -74.75M | -69.90M | -63.36M | -36.71M | -30.26M |
| Net Income | -55.73M | -75.80M | -71.27M | -64.47M | -37.69M | -30.64M |
Balance Sheet | ||||||
| Total Assets | 21.18M | 35.78M | 79.90M | 94.89M | 48.36M | 93.65M |
| Cash, Cash Equivalents and Short-Term Investments | 14.14M | 28.69M | 71.64M | 86.89M | 38.25M | 84.70M |
| Total Debt | 757.00K | 1.24M | 1.81M | 2.79M | 3.65M | 2.88M |
| Total Liabilities | 17.78M | 31.63M | 18.23M | 16.45M | 12.37M | 24.14M |
| Stockholders Equity | 3.40M | 4.15M | 61.67M | 78.44M | 35.99M | 69.52M |
Cash Flow | ||||||
| Free Cash Flow | -68.87M | -77.17M | -63.15M | -52.33M | -46.43M | -36.11M |
| Operating Cash Flow | -68.87M | -77.16M | -62.60M | -52.07M | -45.86M | -33.68M |
| Investing Cash Flow | 1.00K | 5.00K | -532.00K | -267.00K | -576.00K | -2.43M |
| Financing Cash Flow | 34.21M | 34.21M | 47.88M | 100.97M | 55.00K | 100.97M |
Jasper Therapeutics Technical Analysis
Negative
1.02
Price Trends
0.70
Negative
0.93
Negative
1.44
Negative
Market Momentum
-0.08
Negative
38.15
Neutral
41.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JSPR, the sentiment is Negative. The current price of 1.02 is above the 20-day moving average (MA) of 0.46, above the 50-day MA of 0.70, and below the 200-day MA of 1.44, indicating a bearish trend. The MACD of -0.08 indicates Negative momentum. The RSI at 38.15 is Neutral, neither overbought nor oversold. The STOCH value of 41.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JSPR.
Jasper Therapeutics Risk Analysis
Jasper Therapeutics disclosed 82 risk factors in its most recent earnings report. Jasper Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Jasper Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $76.89M | -9.85 | 23.76% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $106.10M | -0.79 | -225.59% | ― | -9.79% | 82.00% | |
48 Neutral | $466.93M | -2.71 | -73.16% | ― | ― | -18.99% | |
47 Neutral | $84.13M | -0.60 | -80.35% | ― | ― | 27.27% | |
43 Neutral | $16.52M | -0.33 | -226.10% | ― | ― | 71.62% | |
40 Underperform | $12.00M | -0.13 | -191.12% | ― | ― | 38.53% |
* Healthcare Sector Average
JSPR
Jasper Therapeutics
0.43
-2.61
-85.92%
CVM
Cel-Sci
1.14
-1.35
-54.22%
BYSI
Beyondspring
1.87
-0.40
-17.62%
CBUS
Cibus
1.39
-0.08
-5.44%
ACET
Adicet Bio
9.00
-0.71
-7.33%
ARTV
Artiva Biotherapeutics, Inc.
9.61
8.03
508.23%
Jasper Therapeutics Corporate Events
Business Operations and StrategyDelistings and Listing ChangesRegulatory Filings and Compliance
Jasper Therapeutics Receives Nasdaq Minimum Bid Price Notice
Negative
Jun 9, 2026
On June 3, 2026, Jasper Therapeutics disclosed that it received a notice from Nasdaq stating its common stock had traded below the $1.00 minimum bid price for thirty consecutive business days, triggering a non-compliance status under Nasdaq Listin...
Business Operations and Strategy
Jasper Therapeutics Launches Strategic Alternatives Review Amid Uncertainty
Negative
Jun 1, 2026
On June 1, 2026, Jasper Therapeutics announced that its board has begun a comprehensive review of strategic alternatives in response to current market conditions, with the stated goal of maximizing shareholder value. Options under consideration ra...
Executive/Board Changes
Jasper Therapeutics Announces Board Resignation and Committee Change
Neutral
May 21, 2026
On May 15, 2026, Jasper Therapeutics, Inc. announced that board member Christian Nolet resigned from the Board of Directors and all board committees, with the company emphasizing that his departure did not stem from any disagreement over its opera...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.